Abstract
Mycophenolic acid (MPA), a standard immunosuppressive drug, is characterized by unexplained highly variable pharmacokinetics in transplant recipients. The primary metabolic pathway of MPA is glucuronidation; however, literature reports are inconsistent and the contribution of all human UDP-glucuronosyltransferases (UGTs) has never been systematically assessed. Sixteen heterologously expressed UGTs were studied for MPA 7-O-glucuronidation and compared with liver, kidney, and intestine microsomes. For direct measurement of MPA and mycophenolic acid 7-O-glucuronide (MPAG), we used a liquid chromatography-mass spectrometry protocol. Metabolic studies demonstrated that the glucuronidation of MPA in humans occurs mainly in the liver at variable rates, as well as in the kidney and the intestine. Kinetic data normalized for UGT expression levels point to 1A8 and 1A9 as the main UGTs, as well as to low-activity enzymes, 1A1, 1A7, and 1A10. According to their expression profiles, 1A8 and 1A9 are proposed, respectively, as the main extra-hepatic and the only hepatic enzymes involved. The effects of naturally occurring 1A8 (*2 and *3) and 1A9 (*2 and *3) variants on MPA 7-O-glucuronidation were studied and data suggest that the C277Y of 1A8 and the M33T of 1A9 may influence MPAG levels. A number of low-activity alleles were also identified in 1A1 [*6 (G71R), *7 (Y486D), *27 (P229Q), and *35 (L233R)], 1A7 [*3 (K129K131R208), *4 (R208), *5 (S115), *8 (K129K131D139R208), and *9 (S115K129K131)], and 1A10 [*2 (E139K)]. Our study provides preliminary evidences that genetic factors, especially in the hepatic UGT1A9, may contribute to the variability of MPA pharmacokinetics observed in transplant patients.
Footnotes
-
This work was supported by the Canadian Institutes of Health Research (CIHR) and the Canada Research Chair Program (C.G.). O.B. is the recipient of a studentship award from the CIHR. C.G. is chairholder of the Canada Research Chair in Pharmacogenomics.
-
ABBREVIATIONS: MPA, mycophenolic acid; UGT, UDP-glucuronosyltransferase; MPAG, mycophenolic acid 7-O-glucuronide; MMF, mycophenolate mofetil; LC/MS, liquid chromatography coupled with mass spectrometry.
- Received January 27, 2004.
- Accepted April 23, 2004.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|